Xavier Leleu, MD Ph.D

Hopital Claude Huriez, CHRU Lille
Service des Maladies du Sang
Rue Michel Polonovski
Lille France

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Xavier Leleu, MD, Ph.D is an Associate Professor in the Department of Haematology at Hôpital Claude Huriez, part of the academic hospital of Lille (CHRU), France. Dr Leleu received his medical degree at the University of Bordeaux, France. He completed specializations in public healthcare and statistics at the University of Medicine of Paris, France and in haematology at the University of Medicine of Lille. He received a Master’s in cellular biology at the University of Medicine of Lille in 2001 and completed his PhD in 2007 having done his research at Dana-Farber Cancer Institute, affiliated with Harvard Medical School, Boston, MA, USA. His main topic of research was the preclinical development of the novel agent and understanding mechanisms of resistance and of dormancy in Waldenström macroglobulinemia and the clinical development of novel agents in multiple myeloma in the context of the most recent discoveryin the biology of Myeloma. He was trained with his mentors Dr IM Ghobrial and Dr SP Treon in Prof. Kenneth Anderson’s laboratory. Dr Leleu is on the editorial board of The Hematologist, Hématologie, and Correspondance en Onco-Hématologie and is a reviewer for several noted journals in the field of haematology including: Blood, Journal of Clinical Oncology, The Lancet Oncol, the British Journal of Haematology, Clinical Cancer Research, Haematologica, and Leukemia, amongst many others. He is also a member of many scientific societies including the American Society of Hematology (ASH), the European Hematology Association (EHA), Intergroupe Francophone du Myélome (IFM), the International Myeloma Working Group (IMWG), and the International Waldenström’s Macroglobulinemia Foundation (IWMF). Dr Leleu has published widely in the field of hematology both in journals and books, and is very active in preclinical and clinical trial research.